K-9 Inflammasome Inhibitor Reverses Motor and Visual Deficits in MS Mouse Model

The Science Translational Medicine study tested K-9 in the EAE mouse model. Treated animals showed reversal of paralysis and optic nerve damage, stable neurofilament light chain levels, and histologic preservation of axons and myelin sheaths. Parallel analysis of insurance claims from over 3 million people found NRTI exposure linked to 41 percent lower MS incidence and 36 percent fewer relapses, providing epidemiologic context for the preclinical results.

Existing MS therapies mainly reduce inflammatory relapses but rarely restore lost function. K-9 blocks inflammasome activation downstream of reverse transcriptase inhibition, a mechanism not targeted by current approved agents. The mouse recovery data therefore address an unmet gap, yet the 3 million-person cohort remains observational and cannot establish causation or rule out confounding by indication.

K-9 has already completed early human testing in diabetic macular edema, shortening the regulatory path for MS trials. Investigators also plan ALS studies where axonal injury and inflammasome activity overlap. Translation hinges on whether the mouse functional gains survive dose-finding and safety studies in patients.

Controlled Phase 1/2 trials in MS are required to measure clinical endpoints, NfL trajectories, and MRI lesion load against standard care. Without these data the mouse reversal and epidemiologic signals remain hypothesis-generating.